Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
The Villages Health System $541.5 Million Settlement: A New Frontier In Medicare Advantage Risk Adjustment Enforcement
The Villages Health System LLC agreed to pay $541.5 million to resolve False Claims Act allegations involving invalid Medicare Advantage diagnosis codes submitted between 2020 and 2024. This landmark settlement demonstrates the Department of Justice's commitment to holding both healthcare providers and Medicare Advantage Organizations accountable for risk adjustment overpayments, while highlighting the value of self-disclosure and cooperation in federal healthcare fraud investigations.
United States Healthcare
BT
Barnes & Thornburg LLP
Article
Eli Lilly To Acquire Merida Biosciences
Eli Lilly announces a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, gaining access to an innovative antibody-engineering platform that selectively targets pathogenic autoantibodies in autoimmune and allergic diseases. The acquisition includes Merida's lead program MER511, currently in Phase 1 development for Graves' disease and thyroid eye disease, along with earlier-stage programs addressing food allergy, asthma, and kidney disease.
United States Healthcare
GP
Goodwin Procter LLP
Article
FDA Sharpens Its Pencil And Oversight Tools On Global Clinical Trial Data
The FDA has signaled heightened scrutiny of global clinical trial data through increased bioresearch monitoring inspections and greater transparency around inspection findings. Sponsors relying on foreign clinical data must meet rigorous good clinical practice requirements, including independent ethics committee review, informed consent, and FDA data validation through on-site inspections.
United States Healthcare
GP
Goodwin Procter LLP
See more

Webinars

See More

Highlighted Content

Food and Drugs Law

Article
That's A Wrap: ASA Serves Up A Feast Of Analysis On Popeyes' Breakfast Ads
The Advertising Standards Authority has issued a detailed ruling on Popeyes' breakfast menu advertisements, examining whether they violated new restrictions on advertising less healthy foods. The case hinged on whether products could be visually distinguished from similar menu items, with the colour of hash brown seasoning becoming a critical factor in the decision.
United States Media & IT
GA
Global Advertising Lawyers Alliance (GALA)
Article
Seventh Circuit Revives Nationwide “Zero Sugar” Class Action, Holds Allulose Is A Sugar Under FDA Regulations
The Seventh Circuit's reversal in Franco v. Chobani has upended food manufacturers' reliance on FDA guidance regarding allulose labeling, creating a wave of class action litigation across the United States. Companies marketing products as "sugar free" despite containing allulose now face significant legal exposure as courts align with the FDA's regulatory definition rather than its enforcement discretion guidance.
United States Consumer
SM
Sheppard, Mullin, Richter & Hampton LLP
Article
FDA Sharpens Its Pencil And Oversight Tools On Global Clinical Trial Data
The FDA has signaled heightened scrutiny of global clinical trial data through increased bioresearch monitoring inspections and greater transparency around inspection findings. Sponsors relying on foreign clinical data must meet rigorous good clinical practice requirements, including independent ethics committee review, informed consent, and FDA data validation through on-site inspections.
United States Healthcare
GP
Goodwin Procter LLP
See more

Healthcare

Article
The Villages Health System $541.5 Million Settlement: A New Frontier In Medicare Advantage Risk Adjustment Enforcement
The Villages Health System LLC agreed to pay $541.5 million to resolve False Claims Act allegations involving invalid Medicare Advantage diagnosis codes submitted between 2020 and 2024. This landmark settlement demonstrates the Department of Justice's commitment to holding both healthcare providers and Medicare Advantage Organizations accountable for risk adjustment overpayments, while highlighting the value of self-disclosure and cooperation in federal healthcare fraud investigations.
United States Healthcare
BT
Barnes & Thornburg LLP
Article
Eli Lilly To Acquire Merida Biosciences
Eli Lilly announces a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, gaining access to an innovative antibody-engineering platform that selectively targets pathogenic autoantibodies in autoimmune and allergic diseases. The acquisition includes Merida's lead program MER511, currently in Phase 1 development for Graves' disease and thyroid eye disease, along with earlier-stage programs addressing food allergy, asthma, and kidney disease.
United States Healthcare
GP
Goodwin Procter LLP
Article
The Tick-ing Time Bomb: Repellents, Regulation, And A Growing Public Health Challenge
Tick-borne diseases are surging across North America and beyond as climate change, ecological shifts, and human behavior converge to expand tick habitats and extend seasonal activity periods. With Lyme disease cases climbing and new tick species establishing themselves in previously unaffected regions, the effectiveness and regulation of insect repellents has become a critical public health concern that varies dramatically across jurisdictions.
Worldwide Government
BC
Bergeson & Campbell
See more

Life Sciences, Biotechnology & Nanotechnology

Article
Eli Lilly To Acquire Merida Biosciences
Eli Lilly announces a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, gaining access to an innovative antibody-engineering platform that selectively targets pathogenic autoantibodies in autoimmune and allergic diseases. The acquisition includes Merida's lead program MER511, currently in Phase 1 development for Graves' disease and thyroid eye disease, along with earlier-stage programs addressing food allergy, asthma, and kidney disease.
United States Healthcare
GP
Goodwin Procter LLP
Article
FDA Sharpens Its Pencil And Oversight Tools On Global Clinical Trial Data
The FDA has signaled heightened scrutiny of global clinical trial data through increased bioresearch monitoring inspections and greater transparency around inspection findings. Sponsors relying on foreign clinical data must meet rigorous good clinical practice requirements, including independent ethics committee review, informed consent, and FDA data validation through on-site inspections.
United States Healthcare
GP
Goodwin Procter LLP
See more

Latest Videos

See more

Upcoming Events